Articles and Videos
Fireside Chat with Roth Capital: InMed’s CEO, Eric A. Adams Sits Down with Roth Analyst Scott Henry
At the 2022 Roth Conference in California, InMed's CEO, Eric A. Adams, sat down with Roth Capital Analyst Scott R. Henry in a fireside chat....
Forbes Health: What is CBN?
Forbes reporter Lauren Silva dives into the science behind rare cannabinoid, cannabinol, also know as CBN. The article features clinical and preclinical research conducted on...
Ophthalmology Times: Blog: Cannabinol, a rare cannabinoid, shows unique therapeutic potential in glaucoma
Excerpt from Ophthalmology Times blog. A recent study of cannabinol in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some...
Ophthalmology Advisor: Cannabinoids May Promote Neuroprotection, Normalize Intraocular Pressure
Excerpt from Ophthalmology Advisor. Using in vitro and in vivo models of glaucoma, cannabinoids (CBs) demonstrated neuroprotection, stopped changes in extracellular matrix (ECM), and normalized intraocular pressure (IOP) levels...
Cannabinoids See Explosive Growth Opportunity | The Dales Report
BayMedica's VP of Commercial Operations, Chris Meiering, joins Shadd Dales of The Dales Report to talk about the growth opportunities in the cannabinoid industry. In...
Source: The Dales Report
InMed at Edison Open House Global Healthcare Conference 2022
InMed's CEO, Eric A. Adams, joins the 2022 Edison Open House Global Healthcare Conference on January 25th. In this discussion, Eric talks about the untapped...
